Aurinia Pharmaceuticals Inc. - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated November 4, 2016, reports on Aurinia Pharmaceuticals Inc.'s Third Quarter 2016 financial results and operational highlights. The filing incorporates Exhibit 99.1 by reference into the company's Registration Statement on Form F-10.
Key Financial Metrics
The provided text serves as a cover sheet and exhibit index. It does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. The filing text does not provide a clear value for these metrics.
Material Changes
No material changes versus the prior comparable period are detailed in the provided text, as the specific financial results are contained within the referenced Exhibit 99.1 rather than the cover document.
Guidance, Outlook, and Risks
The filing text does not include management commentary, guidance, outlook, risks, contingencies, or unusual items. These details are expected to be found in the incorporated Exhibit 99.1.
Investor Verification Checklist
- Review Exhibit 99.1 for the actual Third Quarter 2016 financial results and operational highlights.
- Verify the specific revenue, net loss, and cash burn figures in the full press release.
- Confirm the status of the company's clinical trials and pipeline updates mentioned in the operational highlights.
- Check the Form F-10 Registration Statement (File No. 333-206994) for the full context of the incorporated exhibit.